Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is also engaged in the treatment of skin conditions.
Follow-Up Questions
Who is the CEO of Helix BioMedix Inc?
Ms. Robin Carmichael is the President of Helix BioMedix Inc, joining the firm since 2007.
What is the price performance of HXBM stock?
The current price of HXBM is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Helix BioMedix Inc?
Helix BioMedix Inc belongs to Biotechnology industry and the sector is Health Care
